In summary, our results provide more impetus for considering whether therapeutics that block LIGHT activity could be useful for the treatment of severe asthma, IPF, or the interstitial lung disease characteristic of SSc patients. This evidence concerns the gene TNFSF14 and systemic sclerosis.